Ran Qing-Qi1, Li Ya-Wen1, Chen Huan1, Zhang Yu1,2,3,4,5, An Yun-Fei1,2,3,4,5, Tang Xue-Mei1,2,3,4,5, Zhao Xiao-Dong2,3,4,5,6, Zhang Zhi-Yong7,8,9,10,11. 1. Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400015, China. 2. National Clinical Research Center for Child Health and Disorders, Chongqing, 40015, China. 3. Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, 40015, China. 4. China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, 40015, China. 5. Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, 40015, China. 6. The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China. 7. Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400015, China. zzy510214@216.com. 8. National Clinical Research Center for Child Health and Disorders, Chongqing, 40015, China. zzy510214@216.com. 9. Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, 40015, China. zzy510214@216.com. 10. China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, 40015, China. zzy510214@216.com. 11. Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, 40015, China. zzy510214@216.com.
Abstract
OBJECTIVE: We preformed this retrospective study of clinical manifestation, imaging feature, and mutations to describe joint involvement in X-linked agammaglobulinemia (XLA) patients, aimed to provide recommendation for physicians. METHODS: A total number of 98 XLA patients who have been diagnosed between January 2000 and February 2020 were enrolled and grouped based on whether they developed arthritis and analyzed for the clinical, imaging, and gene mutation data using the t test or the Mann-Whitney test. RESULTS: Forty-five out of 98 patients (45.9%) had joint involvement, 40.8% had symptom prior to the diagnosis of XLA, and 54.1% had no articular symptom. Patients with joint involvement had a higher median diagnostic age of XLA and initial IgG level than patients without it, while their intravenous immunoglobulin was lower (p < 0.05). Knee, hip, and ankle were the most frequent joint, and oligoarthritis (≦ 4 joints) was more common than polyarthritis (88.9% vs 11.1%). Red and tenderness were the most frequent clinical symptoms (80%) with 24.4% reporting limited activity and 8.9% reporting deformity. Imaging data collected from 32 patients indicated that joint effusion (53.3%), synovitis (15.5%), and swollen soft tissue (15.5%) were the most common feature. Seventeen patients were treated by antibiotics plus intravenous immunoglobulin (IVIG) with an effective rate of 70.6%, and 28 patients only received IVIG with an effective rate of 67.9%. In comparison to patients without arthritis who have higher frequency nonsense and frameshift mutation, patients with arthritis had a higher incidence of missense mutation (p < 0.05). CONCLUSION: High prevalence of arthritis among X-linked agammaglobulinemia patients and subsequent progression through IVIG replacement therapy highlight the importance of timely diagnosis and better management of these patients. Our finding indicated a potential correlation between genotype and phenotype, and further research on the mechanism of arthritis in XLA patients could increase physicians' awareness and improve patients' prognosis. Key Points • This study described the feature of arthritis in XLA patients and indicated a potential correlation between this complication and genotype.
OBJECTIVE: We preformed this retrospective study of clinical manifestation, imaging feature, and mutations to describe joint involvement in X-linked agammaglobulinemia (XLA) patients, aimed to provide recommendation for physicians. METHODS: A total number of 98 XLA patients who have been diagnosed between January 2000 and February 2020 were enrolled and grouped based on whether they developed arthritis and analyzed for the clinical, imaging, and gene mutation data using the t test or the Mann-Whitney test. RESULTS: Forty-five out of 98 patients (45.9%) had joint involvement, 40.8% had symptom prior to the diagnosis of XLA, and 54.1% had no articular symptom. Patients with joint involvement had a higher median diagnostic age of XLA and initial IgG level than patients without it, while their intravenous immunoglobulin was lower (p < 0.05). Knee, hip, and ankle were the most frequent joint, and oligoarthritis (≦ 4 joints) was more common than polyarthritis (88.9% vs 11.1%). Red and tenderness were the most frequent clinical symptoms (80%) with 24.4% reporting limited activity and 8.9% reporting deformity. Imaging data collected from 32 patients indicated that joint effusion (53.3%), synovitis (15.5%), and swollen soft tissue (15.5%) were the most common feature. Seventeen patients were treated by antibiotics plus intravenous immunoglobulin (IVIG) with an effective rate of 70.6%, and 28 patients only received IVIG with an effective rate of 67.9%. In comparison to patients without arthritis who have higher frequency nonsense and frameshift mutation, patients with arthritis had a higher incidence of missense mutation (p < 0.05). CONCLUSION: High prevalence of arthritis among X-linked agammaglobulinemia patients and subsequent progression through IVIG replacement therapy highlight the importance of timely diagnosis and better management of these patients. Our finding indicated a potential correlation between genotype and phenotype, and further research on the mechanism of arthritis in XLA patients could increase physicians' awareness and improve patients' prognosis. Key Points • This study described the feature of arthritis in XLA patients and indicated a potential correlation between this complication and genotype.
Authors: Clara Malattia; Maria Beatrice Damasio; Angela Pistorio; Maka Ioseliani; Iris Vilca; Maura Valle; Nicolino Ruperto; Stefania Viola; Antonella Buoncompagni; Gian Michele Magnano; Angelo Ravelli; Paolo Tomà; Alberto Martini Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: Jessica M Lindvall; K Emelie M Blomberg; Jouni Väliaho; Leonardo Vargas; Juhana E Heinonen; Anna Berglöf; Abdalla J Mohamed; Beston F Nore; Mauno Vihinen; C I Edvard Smith Journal: Immunol Rev Date: 2005-02 Impact factor: 12.988
Authors: H Kanegane; T Futatani; Y Wang; K Nomura; K Shinozaki; H Matsukura; T Kubota; S Tsukada; T Miyawaki Journal: J Allergy Clin Immunol Date: 2001-12 Impact factor: 10.793
Authors: Markus G Seidel; Gerhard Kindle; Benjamin Gathmann; Isabella Quinti; Matthew Buckland; Joris van Montfrans; Raphael Scheible; Stephan Rusch; Lukas M Gasteiger; Bodo Grimbacher; Nizar Mahlaoui; Stephan Ehl Journal: J Allergy Clin Immunol Pract Date: 2019-02-15
Authors: S Tsukada; D C Saffran; D J Rawlings; O Parolini; R C Allen; I Klisak; R S Sparkes; H Kubagawa; T Mohandas; S Quan Journal: Cell Date: 1993-01-29 Impact factor: 41.582
Authors: Waleed Al-Herz; Aziz Bousfiha; Jean-Laurent Casanova; Helen Chapel; Mary Ellen Conley; Charlotte Cunningham-Rundles; Amos Etzioni; Alain Fischer; Jose Luis Franco; Raif S Geha; Lennart Hammarström; Shigeaki Nonoyama; Luigi Daniele Notarangelo; Hans Dieter Ochs; Jennifer M Puck; Chaim M Roifman; Reinhard Seger; Mimi L K Tang Journal: Front Immunol Date: 2011-11-08 Impact factor: 7.561